Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

YO4 - Breast Carcinoma disguised as Systemic Sclerosis: A case report of unusual Paraneoplastic Syndrome

Date

07 Dec 2024

Session

Poster Display session

Presenters

Alfred Patrick Mina

Authors

A.P.D. Mina1, E. Bonci2, F. Cardoso3, T. Louro3

Author affiliations

  • 1 Medical Oncology, The Medical City - Augusto P. Sarmeinto Cancer Institute, 1605 - Pasig City/PH
  • 2 Surgical Oncology Department, IOCN - The Oncology Institute Prof. Dr. Ion Chiricuta, 400015 - Cluj-Napoca/RO
  • 3 Breast Unit, Champalimaud Foundation - Champalimaud Clinical Center, 1400-038 - Lisbon/PT

Resources

This content is available to ESMO members and event participants.

Abstract YO4

Case summary

A 70-year-old female initially presented in the clinic for a history of skin thickening, fatigue, weight loss, shortness of breath, and Raynaud’s phenomenon. She consulted an immunologist, and the workup revealed a positive test for antinuclear antibody (ANA) and anti-polymerase III antibody. A diagnosis of systemic sclerosis was made due to the presence of a non-specific interstitial change pattern on the thoracic CT scan. The patient was initially treated with steroids and non-steroidal anti-inflammatory drugs. However, the disease progressed, and treatment was shifted to mycophenolate mofetil and Nintedanib. Two years after the diagnosis, she developed five liver nodules, which were positive for carcinoma of breast cancer origin, hence the diagnosis of metastatic breast carcinoma. The first line of treatment with ribociclib and letrozole was initiated.

Six months after the oncologic treatment initiation, there was a significant clinical improvement in the symptoms, partial response of the liver nodules with no metabolic expression, and stable lung interstitial changes. Currently, the patient continues her breast cancer and systemic sclerosis maintenance treatment. The lack of response to conventional systemic sclerosis therapy but improvement with the underlying malignancy treatment suggests the case’s possible paraneoplastic origin. This case report may further improve awareness of the natural course of the disease, preventing a potential cancer treatment delay.

Clinical trial identification

Editorial acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.